OrsoBio announces positive topline Phase 1b/2a clinical data for its oral mitochondrial protonophore TLC-6740 in combination ...

Sanofi ($SNYNF) announced an update on their ongoing clinical study. Sanofi’s recent clinical study, officially titled ‘A Phase 3, Randomized, ...

Nektar Therapeutics (NASDAQ:NKTR) reported results from its Phase 2b REZOLVE-AA study evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata, with the trial narrowly ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting ...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...

China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura: Paris Friday, December 12, 2025, 09:00 Hrs [IST] The National ...

Investing.com -- South Korean equities have captured investor attention as Macquarie recently released its latest rankings of top performers in the market. The investment bank’s analysis highlights ...